Apple to halt US sales of Series 9, Ultra 2 smartwatches on patent dispute
Company is dealing with a patent dispute over the technology that enables the blood oxygen feature on the devices
18 December 2023 - 18:11
bySamrhitha Arunasalam and Blake Brittain
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Apple will pause sales of its Series 9 and Ultra 2 smartwatches in the US from this week, as it deals with a patent dispute over the technology that enables the blood oxygen feature on the devices. Picture: MIKE SEGAR
Apple said on Monday it would pause sales of its Series 9 and Ultra 2 smartwatches in the US from this week, as it deals with a patent dispute over the technology that enables the blood oxygen feature on the devices.
The move comes after an order in October from the US International Trade Commission (ITC) that could bar Apple from importing its Apple Watches after finding the devices violate medical technology company Masimo’s patent rights.
A presidential review period is in progress on the feature and while the review period will not end until December 25, Apple is preemptively taking steps to comply should the ruling stand, the company said.
The company said it would pause sales of the Watches from its website starting December 21, and from Apple retail locations after December 24.
Both the Series 9 and the Ultra 2 would remain available for purchase outside the US and there would be no impact on units previously bought that include the blood oxygen feature.
Apple believes the ITC’s finding was erroneous and should be reversed and intends to appeal the decision to the Federal Circuit.
Masimo has accused Apple of hiring away its employees, stealing its pulse oximetry technology and incorporating it into the popular Apple Watch.
A jury trial on Masimo’s allegations in California federal court ended with a mistrial in May. Apple has separately sued Masimo for patent infringement in a federal court in Delaware and has called Masimo's legal actions a “manoeuvre to clear a path” for its own competing smartwatch.
A presidential administration has not vetoed an ITC ruling since 2013, when president Barack Obama’s administration overturned an import ban on Apple’s iPhones and iPads from a patent dispute with Samsung.
The Biden administration in February chose not to veto a separate import ban on Apple Watches based on a patent-infringement complaint from medical technology company AliveCor. The ITC has placed the ban on hold for other reasons.
Apple’s wearables, home and accessory business, which includes the Apple Watch, AirPods earbuds and other products, brought in $8.28bn in revenue during the third quarter of 2023, according to a company report.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Apple to halt US sales of Series 9, Ultra 2 smartwatches on patent dispute
Company is dealing with a patent dispute over the technology that enables the blood oxygen feature on the devices
Apple said on Monday it would pause sales of its Series 9 and Ultra 2 smartwatches in the US from this week, as it deals with a patent dispute over the technology that enables the blood oxygen feature on the devices.
The move comes after an order in October from the US International Trade Commission (ITC) that could bar Apple from importing its Apple Watches after finding the devices violate medical technology company Masimo’s patent rights.
A presidential review period is in progress on the feature and while the review period will not end until December 25, Apple is preemptively taking steps to comply should the ruling stand, the company said.
The company said it would pause sales of the Watches from its website starting December 21, and from Apple retail locations after December 24.
Both the Series 9 and the Ultra 2 would remain available for purchase outside the US and there would be no impact on units previously bought that include the blood oxygen feature.
Apple believes the ITC’s finding was erroneous and should be reversed and intends to appeal the decision to the Federal Circuit.
Masimo has accused Apple of hiring away its employees, stealing its pulse oximetry technology and incorporating it into the popular Apple Watch.
A jury trial on Masimo’s allegations in California federal court ended with a mistrial in May. Apple has separately sued Masimo for patent infringement in a federal court in Delaware and has called Masimo's legal actions a “manoeuvre to clear a path” for its own competing smartwatch.
A presidential administration has not vetoed an ITC ruling since 2013, when president Barack Obama’s administration overturned an import ban on Apple’s iPhones and iPads from a patent dispute with Samsung.
The Biden administration in February chose not to veto a separate import ban on Apple Watches based on a patent-infringement complaint from medical technology company AliveCor. The ITC has placed the ban on hold for other reasons.
Apple’s wearables, home and accessory business, which includes the Apple Watch, AirPods earbuds and other products, brought in $8.28bn in revenue during the third quarter of 2023, according to a company report.
Reuters
Apple offers rivals use of mobile payments systems
KATE THOMPSON DAVY: Navigating the treacherous landscape of digital privacy and policy standoffs
When it comes to tech, stick with the tried and tested
Apple suffers setback in bid to rescind €13bn EU tax order
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.